United Therapeutics Q1 2026 Earnings Call Transcript Summary
United Therapeutics reported Q1 2026 earnings with total revenue of $782 million, impacted by severe winter weather and pharmacy operations issues. Tyvaso revenue reached $458 million, driven by growth in Tyvaso DPI. Ralinepag showed strong clinical results in PAH, with the company projecting it could double its patient base to over 30,000 within two years.
Tickers: $UTHR
Topics: clinical_results financial_results market_guidance pharmaceuticals